Christopher J. Helal; Mark Bundesmann; Susan Hammond; Melissa Holmstrom; Jacquelyn Klug-McLeod; Bruce A. Lefker; Dale McLeod; Chakrapani Subramanyam; Oleg Zakaryants; Sylvie Sakata
ACS Med. Chem. Lett., 2019, 10, 8, 1104-1109
https://doi.org/10.1021/acsmedchemlett.9b00205

Abstract

Many pharmaceutical companies have invested millions of dollars in establishing internal chemical stores to provide reliable access to large numbers of building blocks (BB) for the synthesis of new molecules, especially for the timely design and execution of parallel (library) synthesis. Recognizing budget and logistical limitations, we required a more economically scalable process to provide diverse BB. We disclose a novel business partnership that achieves the goals of just-in-time, economical access to com-mercial BB that increases chemical space coverage and accelerates the synthesis of new drug candidates. We believe that this model can be of benefit to companies of all sizes that are engaged in drug discovery by reducing cost, increasing diversity of ana-log molecules in a time-conscious manner, and reducing BB inventory. More efficient use of BB by customers may allow com-mercial vendors to devote a greater portion of their resources to preparing novel BB that increase chemical diversity as opposed to resynthesizing out-of-stock compounds that are inaccessible within company compound collections.